ConductScience.org, home

Paper301783

Incidence of drug-related deaths secondary to high-dose methotrexate and citrovorum factor administration.

Von Hoff DD and 3 others. Cancer Treat Rep, 1977. Cited by 152 papers, by iCite.

Cite this record

ConductScience Library. Incidence of drug-related deaths secondary to high-dose methotrexate and citrovorum factor administration. Papers, record 301783. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/301783

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Incidence of drug-related deaths secondary to high-dose methotrexate and citrovorum factor administration.
PubMed
Journal
Cancer Treat Rep
PubMed
Year
1977
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
152
iCite
Relative citation ratio, by iCite
6.43
iCite
Revised in PubMed
2022-04-08
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Von Hoff DDD D
2Penta JSJ S
3Helman LJL J
4Slavik MM

Source PubMed

Download CSV of authors

Topics6

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
LeucovorinMajor topic
MethotrexateMajor topic
NeoplasmsMajor topic
Drug Therapy, Combination
Humans
United States

Cited by37

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 152 citations.

PMIDTitleJournalYearIn PapersSource
42122187Long-Term Kidney Outcomes in Paediatric Osteosarcoma Survivors: A 20-Year Multi-Centre Study.Cancers (Basel)2026https://conductscience.org/library/papers/42122187PubMed
38186937A Delphi study to determine the epidemiology and clinical management of patients treated with HDMTX who develop methotrexate (MTX) delayed elimination in France, Germany, Italy, and the UK.Health Sci Rep2024https://conductscience.org/library/papers/38186937PubMed
35236714Extracorporeal Treatment for Methotrexate Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup.Clin J Am Soc Nephrol2022https://conductscience.org/library/papers/35236714PubMed
35147457Incidence and management of patients with methotrexate delayed elimination in the clinical practice: A Delphi study.J Oncol Pharm Pract2023https://conductscience.org/library/papers/35147457PubMed
30853983Simultaneous Quantification of Methotrexate and Its Metabolite 7-Hydroxy-Methotrexate in Human Plasma for Therapeutic Drug Monitoring.Int J Anal Chem2019https://conductscience.org/library/papers/30853983PubMed
30799942Length of stay, mortality, and readmissions among Medicare cancer patients treated with glucarpidase and conventional care: a retrospective study.Clinicoecon Outcomes Res2019https://conductscience.org/library/papers/30799942PubMed
28856465Guidelines for treatment of renal injury during cancer chemotherapy 2016.Clin Exp Nephrol2018https://conductscience.org/library/papers/28856465PubMed
24132809Efficacy of glucarpidase (carboxypeptidase g2) in patients with acute kidney injury after high-dose methotrexate therapy.Pharmacotherapy2014https://conductscience.org/library/papers/24132809PubMed
23760811Between-course targeting of methotrexate exposure using pharmacokinetically guided dosage adjustments.Cancer Chemother Pharmacol2013https://conductscience.org/library/papers/23760811PubMed
22652833Clinical relations of methotrexate pharmacokinetics in the treatment for pediatric osteosarcoma.J Cancer Res Clin Oncol2012https://conductscience.org/library/papers/22652833PubMed
22432089High dose methotrexate and extended hours high-flux hemodialysis for the treatment of primary central nervous system lymphoma in a patient with end stage renal disease.Am J Blood Res2012https://conductscience.org/library/papers/22432089PubMed
21301589Cancer chemotherapy: targeting folic acid synthesis.Cancer Manag Res2010https://conductscience.org/library/papers/21301589PubMed
11192475Clinical and preclinical pharmacokinetics of raltitrexed.Clin Pharmacokinet2000https://conductscience.org/library/papers/11192475PubMed
8599863High-dose 7-hydromethotrexate: acute toxicity and lethality in a rat model.Cancer Chemother Pharmacol1996https://conductscience.org/library/papers/8599863PubMed
8194163Renal and hepatic toxicity after high-dose 7-hydroxymethotrexate in the rat.Cancer Chemother Pharmacol1994https://conductscience.org/library/papers/8194163PubMed
7735697Interaction between methotrexate and indomethacin on a human normal haemopoietic cell line.Br J Pharmacol1995https://conductscience.org/library/papers/7735697PubMed
7726679Glutamine enhances selectivity of chemotherapy through changes in glutathione metabolism.Ann Surg1995https://conductscience.org/library/papers/7726679PubMed
7250179Effect of urine pH and flow on renal clearance of methotrexate.Eur J Clin Pharmacol1981https://conductscience.org/library/papers/7250179PubMed
6994913The practical benefits of pharmacokinetics in the use of antineoplastic agents.Cancer Chemother Pharmacol1980https://conductscience.org/library/papers/6994913PubMed
6781586Methotrexate treatment of squamous-cell head and neck cancers: dose-response evaluation.Br Med J (Clin Res Ed)1981https://conductscience.org/library/papers/6781586PubMed

See all 37 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/301783

GET https://conductscience.org/api/papers/v1/301783/cited_by?page=2